D. Boral Capital Lowers Carisma Therapeutics (NASDAQ:CARM) Price Target to $1.00

Carisma Therapeutics (NASDAQ:CARM) had its target price lowered by D. Boral Capital from $12.00 to $1.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. D. Boral Capital’s target price suggests a potential upside of 350.05% from the stock’s previous close.

A number of other research firms have also commented on CARM. Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $10.00 to $1.00 in a research note on Thursday, December 12th. Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Evercore ISI reissued an “in-line” rating and issued a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Finally, BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Carisma Therapeutics presently has an average rating of “Hold” and a consensus price target of $2.74.

Carisma Therapeutics Price Performance

CARM stock opened at $0.22 on Tuesday. The stock’s 50 day moving average price is $0.43 and its 200 day moving average price is $0.66. The firm has a market cap of $9.28 million, a P/E ratio of -0.14 and a beta of 1.55. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. Carisma Therapeutics has a 1 year low of $0.20 and a 1 year high of $2.05.

Hedge Funds Weigh In On Carisma Therapeutics

A number of hedge funds have recently made changes to their positions in CARM. Wexford Capital LP raised its position in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares during the period. Renaissance Technologies LLC grew its position in Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after acquiring an additional 24,600 shares during the period. Finally, Barclays PLC increased its stake in Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.